CCR presentations at AACR 2017

Several CCR scientists will present their research at the AACR Annual Meeting in Washington, D.C., between April 1-5, 2017. Selected oral presentations are listed below. A full list of abstracts can be found on the AACR website.

April 1, 2017

Time Title Authors Session
10:15 - 12:15 PM Immunotherapy combination strategies James L. Gulley. NCI-CCR ED18 - Cancer Immunology for the Non-Immunologist: Tutorial
12:00 - 5:00 PM Constructing a strong career development proposal Javed Khan. NCI-CCR PAS01 - Twentieth Annual Grant Writing Workshop, Organized by the Associate Member Council (AMC)
9:00 - 9:25 AM PARP trapping, replicative damage and Schlafen 11 Yves G. Pommier. NCI-CCR ED23 - Synthetic Lethality for treating DNA Repair Defective Human Cancer
9:30 - 9:50 AM Spontaneous canine malignancies: Models for precision cancer medicine Amy K. LeBlanc. NCI-CCR MW04 - Application of Novel Models to Guide Individual Therapies

April 2, 2017

Time Title Authors Session
1:05 - 1:30 PM Precision medicine: Lung biomarkers Curtis C. Harris. NCI-CCR SY37 - Lung Cancer Outcomes: Clinical Implications For Smoking
3:20 - 3:35 PM CLIC4 is incorporated into extracellular vesicles of murine breast cancer cells and may influence metastatic burden Alayna B. Craig-Lucas, Vanesa C. Sanchez, Abigail Read, Ji Lou, Anjali Shukla, Stuart H. Yuspa. NCI-CCR MS.TB04.01 - Niches and Routes of Metastasis
3:35 - 3:50 PM Directionality of T-cell-mediated cross-protection against the same tumor in lungs versus skin Jessica J. O'Konek, Elena Ambrosino, Anja Bloom, Liat Izhak, Jay A. Berzofsky, Masaki Terabe. NCI-CCR MS.IM01.01 - Novel Insights into Mechanisms of Response to Immunotherapy
3:50 - 4:05 PM Progression from melanocytic nevi to melanoma is associated with increased genomic mutations in a UV-induced mouse model of human melanoma Helen Michael, Chi-Ping Day, Howard Yang, Aleksandra Michalowski, Maxwell Lee, Glenn Merlino. NCI-CCR MS.TB01.01 - Animal Models of Human Oncogenesis
4:35 - 4:50 PM Role of endocytosis in NM23 mediated motility suppression Imran Khan, Patricia S. Steeg. NCI-CCR MS.TB04.01 - Niches and Routes of Metastasis

April 3, 2017

Time Title Authors Session
1:35 - 2:00 PM Microbes in cancer: Friends or foes? Giorgio Trinchieri. NCI-CCR SY43 - Inflammation and Cancer
3:15 - 4:00 PM An Update from the NCI's Acting Director Douglas R. Lowy. NCI-CCR LE12 - An Update from the NCI's Acting Director
3:20 - 3:35 PM Gut microbiome controls liver metastasis Chi Ma, Qiong Fu, Tim Greten. NCI-CCR MS.TB06.02 - Tumor and Stromal Cell Interactions
3:20 - 3:35 PM Polymorphisms in the arntl2 promoter affect breast cancer metastasis susceptibility Ngoc-Han Ha, Kent Hunter. NCI-CCR MS.TB04.02 - Early Stages of Metastatic Dissemination
3:35 - 3:50 PM The antitumor activity of immunotoxins is enhanced by tofacitinib Nathan Simon1, Antonella Antignani1, Stephen Hewitt1, Massimo Gadina2, Masanori Onda1, Christine Alewine1, David Joseph Fitzgerald1. 1NCI-CCR; 2NIAMS MS.IM02.02 - Adaptive Immunity in the Tumor Microenvironment
3:50 - 4:05 PM Exome analysis of known hereditary cancer genes in 122 children with rhabdomyosarcoma Talia Wegman-Ostrosky1, Rajesh Patidar1, Sivasish Sindiri1, Jack Shern1, Douglas S. Hawkins2, Daniel Catchpoole3, Jun S. Wei1, Stephen Skapek4, Javed Khan1, Douglas R. Stewart1. 1NCI; 2Seattle Children's; 3University of Sydney; 4UT Southwestern Department of Pediatrics MS.CL02.TB08.01 - Predictors and Drivers of Pediatric Tumors
4:05 - 4:20 PM Polyfunctional anti-CD19 CAR T cells determined by single-cell multiplex proteomics associated with clinical activity in patients with advanced non-Hodgkin’s lymphoma John Rossi1, Patrick Paczkowski2, Yueh-wei Shen1, Kevin Morse2, Brianna Flynn2, Alaina Kaiser2, Colin Ng2, Kyle Gallatin2, Tom Cain2, Rong Fan3, Sean Mackay2, James Heath4, Steven A. Rosenberg5, James N. Kochenderfer6, Jing Zhou2, Adrian Bot1. 1Kite Pharma; 2IsoPlexis; 3Yale School of Engineering and Applied Science; 4Division of Chemistry and Chemical Engineering, California Institute of Technology; 5Surgery Branch, NCI-CCR; 6Experimental Transplantation and Immunology Branch, NCI-CCR MS.CL10.01 - Clinical Biomarkers
4:05 - 4:20 PM Preclinical characterization of a novel monoclonal antibody targeting a neo-antigen expressed in ovarian and GI malignancies Kristen Zeligs1, Philip M. Arlen2, Kwong Tsang2, Lidia Hernandez3, Massimo Fantini2, Christina M. Annunziata3. 1Walter Reed National Military Medical Center; 2Precision Biologics, Inc.; 3NCI-CCR MS.IM02.02 - Adaptive Immunity in the Tumor Microenvironment
4:05 - 4:20 PM Direct regulation of alternative splicing by Smad3 through PCBP1 is essential to the tumor-promoting role of transforming growth factor beta1 Veenu Tripathi, Katherine M. Sixt, Xuan Xu, Ying E. Zhang. NCI-CCR MS.MCB01.01 - Breakthroughs in the Control, Function, and Drivers of Oncogenesis
4:05 - 4:20 PM Comparison of somatic alterations in the genome and transcriptome of 1,705 pediatric leukemia and solid tumors: a report from the Children’s Oncology Group (COG) - NCI TARGET Project Xiaotu Ma1, Yu Liu1, Yanling Liu1, Michael Edmonson1, Charles Gawad1, Xin Zhou1, Yongjin Li1, Michael Rusch1, John Easton1, Mark Wilkinson1, Leandro C. Hermida2, Sean Davis2, Malcolm Smith2, Jaime Guidry Auvil2, Paul Meltzer2, Ching C. Lau3, Elizabeth Perlman4, John M. Maris5, Soheil Meshinchi6, Stephen P. Hunger5, Daniela S. Gerhard2, Jinghui Zhang1. 1St Jude Children's Research Hospital; 2NCI; 3Texas Children's Cancer and Hematology Centers; 4Ann and Robert H. Lurie Children's Hospital of Chicago; 5Children's Hospital of Philadelphia; 6Fred Hutchinson Cancer Research Center MS.CL02.TB08.01 - Predictors and Drivers of Pediatric Tumors
4:50 - 5:05 PM Pharmacokinetic and pharmacodynamic analysis of M7824, a dual anti-PD-L1 and TGFβ TRAP molecule, in the first-in-human phase I dose escalation study Liang Cao1, Zhigang Kang2, Linghui Li3, Julius Strauss4, Isabelle Dussault3, James Gulley1. 1NCI-CCR; 2Leidos Biomedical Research Inc./NCI-CCR; 3EMD Serono; 4Leidos Biomedical Research Inc. CTMS02 - Update, Novel Indication, and New Immuno-oncology Clinical Trials
5:15 - 6:00 PM Lymphoma therapy inspired by functional and structural genomics  Louis M. Staudt. NCI-CCR Eleventh Annual AACR Princess Takamatsu Memorial Lectureship 

April 4, 2017

Time Title Authors Session
3:00 - 5:00 PM Chair Christian Hinrichs. NCI-CCR MS.IM02.01 - Adoptive Cellular Therapy for Cancer
3:05 - 3:20 PM Dynamic reprogramming of the chromatin landscape in cancer: Studies in real time Ville Paakinaho, Diego M. Presman, Erin E. Swinstead, Tina B. Miranda, David A. Ball, Tatiana S. Karpova, Gordon L. Hager. NCI-CCR MS.MCB04.01 - Transcriptional Regulation in Cancer Cells
3:20 - 3:35 PM Miswired super enhancer logic driving childhood sarcoma Berkley E. Gryder1, Marco Wachtel2, Hsien-Chao Chou1, Young Song1, Joana Marques2, Beat Schaefer2, Javed Khan1. 1NCI-CCR; 2University Children's Hospital, Zurich, Switzerland MS.MCB04.01 - Transcriptional Regulation in Cancer Cells
4:20 - 4:35 PM Regression of metastatic breast cancer after adoptive cell transfer of tumor infiltrating lymphocytes and checkpoint blockade Nikolaos Zacharakis1, Katarzyna Trebska-McGowan2, Robert Somerville1, Yong-Chen Lu1, Anna Pasetto1, Mary Black1, Harshini Chinnasamy1, Hui Xu1, Jared J. Gartner1, Todd D. Prickett1, Paul F. Robbins1, Steven A. Rosenberg1, Stephanie L. Goff1, Steven A. Feldman1. 1NCI-CCR; 2Virginia Commonwealth University MS.IM02.01 - Adoptive Cellular Therapy for Cancer
4:20 - 4:35 PM Impaired PARP1 DNA repair defines chemosensitivity in IDH1 mutant cell Yanxin Lu, Yang Liu, Yu-Ting Su, Wendy Bautista, Mark R. Gilbert, Jing Wu, Chunzhang Yang. NCI-CCR MS.ET01.01 - Novel Approaches for Experimental Therapeutics

April 5, 2017

Time Title Authors Session
10:20 - 10:45 AM Mechanisms of oncogenic signaling and therapeutic resistance in lymphoma revealed by CRISPR-Cas9 screens  Louis M. Staudt. NCI-CCR SY09 - CRISPR and Functional Genomics 
10:50 - 11:15 AM Defining the limitations of CD19CAR immunotherapy in pediatric ALL and development of effective countermeasures Terry J. Fry. NCI-CCR SY20 - CAR T Cell Cancer Immunotherapy: Refinements for B Cell Malignancies and Emerging Opportunities in Solid Tumors